Molecular Pathology of Head and Neck Cancer
|
Molecular Pathology of Head and Neck Cancer |
About Contact |
| Home | • | Compounds | • | Expert Opinion | • | Trial Analysis | • | Pathways | • | Diseases | • | Workspace | • | TOUR |
 |
|
| Welcome to CuraBase® - The Curated and Collaborative Cancer Database Click Here to Learn More about CuraBase® |
|
Access to CuraBase® is free-of-charge for users in Academia or Non-Profit Organizations. |
|
| Region | Incidence Overall | Incidence Males | Incidence Females | Deaths Overall | Deaths Males | Deaths Females |
|---|---|---|---|---|---|---|
| USA | 36540 | 25420 | 11120 | 7880 | 5430 | 2450 |
| Source: American Cancer Society. Cancer Facts & Figures 2010. Atlanta: American Cancer Society; 2010 | ||||||
| Affected Protein | Pathway | Sub-Type | Ethnicity | Stage | Frequency (%) | Gene Amplification | Activating Mutation | Inactivating Mutation | Deletion | Promoter Hypermethylation | Comment | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C-Myc | Cell Cycle Regulation |
HNSCC | 9% | |||||||||
| Cyclin D1 | Cell Cycle Regulation |
primary head and neck squamous carcinomas | 34 - 37% | |||||||||
| EGFR (ErbB-1 receptor) | Receptor Tyrosine Kinase Signaling |
HNSCC | 7–19% | |||||||||
| Pi3-kinase | PI3-Kinase Signaling |
sporadic HNSCC | 11% | |||||||||
| PTEN | PI3-Kinase Signaling |
23% |
| CANCER.GOV PDQ® - Standard Treatments for Head and Neck Cancer | ||
